Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Rang in aandelen #4536
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aandeelprijs
$27.18
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$3.38B
Verandering (1 dag)
-1.41%
Verandering (1 jaar)
197.05%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)

Categorie

Healthcare
EPS voor Tango Therapeutics, Inc. (TNGX)
EPS per June 2026 TTM: $-0.85
Volgens de laatste financiële rapporten en de aandelenkoers van Tango Therapeutics, Inc. is de huidige EPS van het bedrijf (TTM) $-0.85. Eind 2023 had het bedrijf een EPS van $-1.08, een daling ten opzichte van de EPS van 2022 die $-1.23 bedroeg.
EPS-geschiedenis van Tango Therapeutics, Inc. van 2019 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) $-0.85 -28.57%
2024 $-1.19 10.19%
2023 $-1.08 -12.20%
2022 $-1.23 30.85%
2021 $-0.94 -41.98%
2020 $-1.62 3.18%
2019 $-1.57 0.00%
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$17.32 -2,137.65%
US
$-7.98 838.82%
US
$-5.29 522.35%
AU
- -
CH
$27.74 -3,363.53%
NL